Free Trial
NASDAQ:MDXG

MiMedx Group Q2 2025 Earnings Report

MiMedx Group logo
$6.77 -0.08 (-1.17%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$6.76 0.00 (-0.07%)
As of 07/25/2025 07:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MiMedx Group EPS Results

Actual EPS
N/A
Consensus EPS
$0.06
Beat/Miss
N/A
One Year Ago EPS
N/A

MiMedx Group Revenue Results

Actual Revenue
N/A
Expected Revenue
$90.79 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

MiMedx Group Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Wednesday, July 30, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

MiMedx Group Earnings Headlines

Trump’s $100 Trillion Land Rush Is On
What Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trillions in oil, gas, lithium, and land rights. Whitney Tilson breaks it all down, and shows how everyday Americans can grab a stake. His urgent new briefing explains "The US: IPO"... and how to get in before the looming federal deadline.
See More MiMedx Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MiMedx Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MiMedx Group and other key companies, straight to your email.

About MiMedx Group

MiMedx Group (NASDAQ:MDXG). develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

View MiMedx Group Profile

More Earnings Resources from MarketBeat